Início › Síndromes Mielodisplásicas › Kentucky
Ensaios clínicos de Síndromes Mielodisplásicas em Kentucky
5 estudos para Síndromes Mielodisplásicas estão buscando participantes em locais em Kentucky.
Cidades em Kentucky
Texto oficial do estudo (Inglês)
Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)
- The James Graham Brown Cancer Center at University of Louisville, Louisville
- UofL Health Medical Center Northeast, Louisville
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT06577441MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- University of Kentucky/Markey Cancer Center, Lexington
- The James Graham Brown Cancer Center at University of Louisville, Louisville
- UofL Health Medical Center Northeast, Louisville
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT05564390A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
- Norton Cancer Institute, Louisville
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 18 de set. de 2026 · NCT07422480The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- University of Kentucky/Markey Cancer Center, Lexington
- Norton Children's Hospital, Louisville
RecrutandoFase 1/2
Até 22 anos · Todos os sexos · Atualizado em 25 de ago. de 2026 · NCT04726241A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
- Norton Cancer Institute, Louisville
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 21 de ago. de 2026 · NCT06499285Fonte: ClinicalTrials.gov, dados obtidos em 5 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.